Early Access — free while we kick the tires
EdgarHawk

DECKER SHARON A

Director

Director
2 filings analyzed · 1 company · Latest 2024-09-27

Companies

Company Buys Sells Direction
CULP INC CULP 2 0 Net buying

Activity

September 2024
2024-09-27 CULP INC CULP
low
Buy
5,000 shares
$29,950
Significance 3/10

Director DECKER SHARON A buys 5,000 shares of CULP at $5.99; company unprofitable, revenue declining.

Director Sharon A. Decker purchased 5,000 shares at $5.99 on 2024-09-26, increasing her holdings by 12.4% to 45,383 shares post-transaction. This open-market buy occurs against a backdrop of fundamental weakness: the company generated negative net income of $-7,261,000.00 in its latest quarter and annual revenue declined 4.1% year-over-year. The stock has recovered 17.8% over the past 30 days and 33.3% over 90 days, trading 7.7% below its 52-week high. However, the insider's cross-ticker track record shows prior open-market buys averaging -8.6% returns at the 30-day mark, and her sole prior CULP purchase on 2024-07-18 has also posted a -8.6% 30-day return. Timing does not appear to be a strength in this insider's transaction history.

July 2024
2024-07-19 CULP INC CULP
high
Buy
5,000 shares
$25,978
Significance 6/10

Director Decker buys 5,000 shares of CULP at $5.20; 4 other insiders also bought in past 14 days amid -4.1% revenue decline and recent unprofitability.

Director Sharon A Decker purchased 5,000 shares at $5.20 on 2024-07-18, expanding her position by 19.6% to 30,544 shares post-transaction. This purchase occurs within a cluster pattern: 4 other insiders have also bought within the past 14 days, suggesting concurrent appetite at the director level despite the company's recent headwinds. CULP reported a net loss of $-3.2M in the latest quarter and full-year net income was negative, while annual revenue contracted by 4.1% year-over-year. The stock has recovered +21.8% over the past 30 days and +16.7% over 90 days, trading currently at $5.30, placing it 9.2% below its 52-week high of $5.84. The synchronized insider accumulation alongside operational challenges and recent price recovery warrants investor attention to the board's view of near-term direction and valuation.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access